Table of Content


Summer 2005, Vol. 13 No. 2

Hong Kong J. Dermatol. Venereol. (2005) 13, 74-82

Review Article

A review of imiquimod in the treatment of non-lymphoma cutaneous malignancy

WK Tang 鄧偉祺

Imiquimod is a topical immune response modifier. It is licensed for genital warts, actinic keratosis, and recently basal cell carcinoma. Studies showed that it had potent anti-tumour activity by enhancing both innate and acquired immunity. A growing number of evidences are found to support the use of imiquimod in various kinds of cutaneous malignancies, especially in basal cell carcinoma. Imiquimod was also documented as a useful treatment option for squamous cell carcinomas, squamous cell carcinoma in-situ, lentigo maligna, and extramammary Paget's disease, in immunocompetent and immunosuppressed patients. Imiquimod may be a novel treatment option worthy of consideration for carefully selected patients in whom traditional therapy is not considered feasible. This article reviews the published articles in English literature with keywords-imiquimod, basal cell carcinoma, squamous cell carcinoma, squamous cell carcinoma in-situ, lentigo maligna, extramammary Paget's diseases. Lymphoma, lymphomatoid or lymphomatous malignancy/cies were excluded in the literature search.